Inhibition of certain metabolic processes has been shown to be the property of various central nervous system depressants (1, 2) and a parallelism exists between in vitro and in vivo effects. Furthermore, the structure activity relationship of various psychopharma cological agents has been shown to be due to their interaction with receptor surfaces (3). Amongst 2,3-disubstituted quinazolones possessing central nervous system depressant activity (4-6), 2-methyl-3-(o-tolyl)-4-quinazolone (QZ-2) was found to be a potent anticonvulsant as compared to sodium phenobarbitone against pentylenetetrazole induced seizures (7). Such quinazolones exhibiting profound influence on the normal functional activity of the brain, were found to inhibit selectively nicotinamide adenine dinucleotide (NAD) dependent oxidation of the substrates of tricarboxylic acid cycle, L-glutamate and 19-hydroxybutyrate (8, 9). The ability of quinazolone allyl ethers and quinazolone allyl phenols to inhibit the oxidation of pyruvic acid by rat brain homogenate (10) led us to in vestigate the effects of these quinazolones on the oxidation of NAD-dependent and NAD independent substrates. In the present study attempts have also been made to correlate the enzyme (s) inhibitory activity of quinazolone allyl ethers and quinazolone allyl phe nols with their anticonvulsant property.
Determination of respiratory activity of rat brain homogenate
Male albino rats, kept on an ad libitum diet, were used in all experiments. All incu bations were carried out in the conventional Warburg manometric apparatus at 37° with air as the gas phase. Fresh rat brain homogenate (0.3 ml) equivalent to 400 mg wet weight was added to chilled Warburg vessels containing 6.7 mm MgSO,, 20 mm Na,HPO, buffer solution (pH 7.4), 1 mm adenosine monophosphate (Na salt), 33 mm KCI, and 500
,ug of cytochrome-C in a final volume of 3 ml unless otherwise stated. The central well contained 0.2 ml of 20% KOH solution.
Determination of anticonvulsant activity
Metrazol seizures threshold test : Anticonvulsant activity was determined in rats of either sex weighing between 80 to 100 g. The rats were divided into groups keeping the group weight equal as far as possible. One group of ten animals was used for each dose of the compound. Quinazolone allyl ethers and quinazolone allyl phenols suspended in 5% aqueous gum acacia were fed orally. Six hours after the administration of the test compounds pentylenetetrazol (Metrazol) was injected subcutaneously under the loose skin of the back in a dose of 80 mg/kg. This dose of pentylenetetrazol has been shown to cause convulsions in almost all normal animals. The animals were observed for next 60 minutes for the occurrence of seizures. An episode of clonic spasm which persisted for at least 5 seconds period was considered a threshold convulsion. Transient inter mittent jerks of tremulousness was not taken into account. Animals not exhibiting even a threshold convulsion during a period of 60 minutes were considered protected. The number of animals protected in each group was recorded and the percentage protection was determined for each dose of the test compounds. The mortality was recorded after 24 hours to obtain an idea of the toxicity of the quinazolone in pentylenetetrazol treated animals.
RESULTS AND DISCUSSION
The effects of quinazolone allyl ethers and quinazolone allyl phenols on the NAD dependent and NAD-independent oxidation of the substrates of the tricarboxylic acid cycle, L-glutamate, and (3-hydroxybutyrate by rat brain homogenate are reported in Tables  1 and 2 respectively. As is evident from inhibited the oxidation of sodium citrate, a-ketoglutarate, L-glutamate, Q-hydroxybutyrate and sodium fumarate except the NAD-independent oxidation of sodium succinate where no such inhibition was observed. Introduction of chloro-, bromo-, or iodo-substituent at position 6 of the quinazolone nucleus was found to decrease the inhibition of NAD dependent oxidation of all the substrates. In general the electronegativity of the halogen substituent at position 6 was found to have no significant effect on the degree of inhibi tion. These results have provided further support for specific inhibition of the NAD dependent dehydrogenases concerned with the oxidation of these substrates by compounds possessing quinazolone moiety. These compounds, on the other hand, were found to have no effect on the oxidation of succinate (Table 1) where such an oxidation is independent of NAD. Similar results have been reported by other investigators (8) (9) (10) (11) where inhibition of the oxidation of glucose, pyruvate, malate and glutamate by rat brain homogenate was observed by certain hypnotics such as phenobarbitone, glutethimide and 2-methyl-3
(ortho-tolyl)-4-quinazolone.
In an attempt to investigate the effect of an another substituent at position 8, in addition to one at position 6 of the quinazolone nucleus, 6, On the other hand no change in the inhibition was observed during oxidation of L-glutamate and fumarate while such inhibi tion was found to increase when citrate was used as the substrate. As is evident from Table 1 , the ability of 2-methyl-6-bromo-3-(4'-allyloxy phenyl)-4-quinazolone to inhibit the oxidation of L-glutamate, fumarate, citrate and Q-hydroxybutyrate was found to increase with 2-methyl-6, 8-dibromo-3-(4'-allyloxy phenyl)-4-quinazolone while such an inhibition was found to be significantly reduced during the oxidation of o -ketoglutarate. The quinazolone allylphenols were also found to inhibit the oxidation of different substrates of the tricarboxylic acid cycle except the succinate where no such inhibition was observed ( Table 2) .
The inhibitory effects of 2-methyl-3-(3'-allyl-4'-hydroxy phenyl)-4-quinazolone were found to be greater than the corresponding quinazolone allyl ether [2-methyl-3-(4'-allyloxyphenyl)-4-quinazolone].
In this series too, the degree of inhibition was found to decrease by introduction of chloro-, bromo or iodo substituent at position 6 of the quinazolone nucleus. Under similar experimental condi tions, no inhibition could be observed by 6-substituted quinazolone allyl phenols during the oxidation of a-ketoglutarate. Introduction of an additional chloro or bromo-sub stituent at position 8 yielding 6, 8-dichloro or 6, 8-dibromo derivatives were found to ex hibit greater inhibition than the corresponding 6-substituted derivatives during oxidation of L-glutamate, fumarate and (3-hydroxybutyrate. On the other hand no inhibition could be observed during oxidation of cc-ketoglutarate while decrease in the degree of inhibition was observed when citrate was used as the substrate. These results have failed to provide any structure activity relationship of the quinazolone allyl ethers and quinazolone allyl phenols with respect to their ability to inhibit selectively the NAD-dependent oxidations of the tricarboxylic acid cycle, L-glutamate and Q-hydroxybutyrate. These results are in agreement with earlier investigations (12) where decrease in the inhibitory effects of the quinazolones were observed by introduction of a substituent at either position 6 or posi tions 6 and 8 of the quinazolone nucleus.
The anticonvulsant activity exhibited by quinazolone allyl ethers and quinazolone allyl phenols is shown in Tables 3 and 4 respectively. The quinazolone allyl ethers were tested in doses of 100 mg/kg in albino rats. It was observed that 2-methyl-3-(4' allyloxy phenyl)-4-quinazolone produced 20% protection. Substitution at position 6 of the quinazolone nucleus with chloro-, bromo or iodo-substituent was found to decrease the degree of protection to 10%. Such protection with 2-methyl-6, 8-dichloro-3-(4' * Compounds were tested at the dose of 100 mg/kg. Table  3 all the quinazolone allyl ethers produced 10% mortality except 2-methyl-3-(4'-allyloxy phenyl) -4-quinazolone. The anticonvulsant activity exhibited by quinazolone allyl phenols at the dose of 150 mg/kg is shown in Table 4 . The quinazolone allyl phenol prepared from unsubstituted anthranilic acid [2-methyl-3-(3'-allyl-4'-hydroxyphenyl)-4-quinazolone] showed 30% pro tection. On the other hand introduction of chloro-, bromo-, or iodo-substituents at posi tion 6 of the quinazolone nucleus resulted in the decrease in their ability to afford protec tion against pentylentetrazole induced seizures. Similar decrease in the anticonvulsant property was observed with quinazolone allyl phenols having chloro or bromo substituents at both 6 and 8 positions. All these quinazolone allyl phenols exhibited 40% mortality during 24 hours period except 6-iodo-2-methyl-3-(3'-allyl 4'-hydorxy phenyl)-4-quinazo lone and 6, 8-dibromo-2-methyl-3-(3'-allyl 4'-hydroxy phenyl)-4-quinazolone where only 10% mortality was observed.
These results have indicated slight relationship between anticonvulsant properties of the quinazolone allyl ethers and quinazolone allyl phenols with their ability to inhibit NAD dependent oxidations. The substitution effects as observed by decrease in the inhibition were reflected by a similar decrease in the anticonvulsant properties of these quina zolones. The low protection afforded by these quinazolones against pentylenetetrazol induced seizures has failed to represent anticonvulsant property as a basis for the inhibi tion of NAD-dependent oxidations. It is hoped that our further studies could possibly attribute suitable pharmacological properties of these quinazolone allyl ethers and allyl phenols to their ability to inhibit NAD-dependent oxidations.
SUMMARY
Substituted quinazolone allyl phenols and quinazolone allyl ethers were investigated on the respiratory activity of rat brain homogenate. All the quinazolones were found to inhibit selectively NAD-dependent oxidation of substrates of tricarboxylic acid cycle, L-glutamate and Q-hydroxy butyrate except sodium succinate where no inhibition was observed. Introduction of a substituent at position 6 or position 6 and 8 of both series of quinazolones resulted in a significant decrease in the inhibitory activity. Quinazolone allyl phenols were found to exhibit greater anticonvulsant property against metrazol in duced seizures as compared to quinazolone allyl ethers.
